VERCIRNON – GSK1605786A (formerly CCX282-B) Anti-inflammatory intended to treat Crohn’s disease and inflammatory bowel disease
|Synonym:||CCX282-B, GSK1605786, GSK 1605786|
- Average mass: 444.931091
Anti-inflammatory intended to treat Crohn’s
disease and inflammatory bowel disease
GSK1605786A (formerly CCX282-B) targets chemokine receptor CCR9, which is expressed selectively on intestinal lymphocytes and dendritic cells. CCR9 mediates migration of immune cells to the intestine, and blockade of the receptor inhibits migration.
GSK1605786A is being studied in CD at a dose of 500 mg by mouth once daily or 500 mg by mouth twice daily versus placebo. Final data is anticipated to be collected mid-2012 for a study evaluating efficacy over a 12-week treatment period.
A study reviewing maintenance of remission is expected to be complete in July 2014 and a long-term safety study is scheduled for completion in July 2015.
GSK-1605786 (CCX-282; Traficet-EN), a selective antagonist of the CC chemokine receptor (CCR9)…
View original post 347 more words